secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001628908-23-000119
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Q2 revenue up 47% to $469M, raises 2023 Adj. EBITDA guidance; redeems $24.3M convertible notes
--------------------------------------------------------------------------------

- Revenue $469.1M (+46.6% YoY); net loss $41.4M; adjusted EBITDA $47.4M (10.1% margin).
- Total Lives on Platform 78.6M (from 19.4M); average unique members 41.8M (from 16.3M).
- Signed 2 new operating partners (Molina Florida, regional non-profit) and 2 expansions; YTD 6 deals vs target 6-8.
- CEO raises 2023 Adj. EBITDA guidance; reaffirms $300M run-rate target exiting 2024.
- Redeeming $24.3M of 3.50% convertible notes due 2024 on Oct 13 for cash (100% principal + interest).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890823000119/0001628908-23-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890823000119/evh-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001628908-23-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer